RSV A Memphis 37
PreclinicalBiologic
RSV A Memphis 37 is one of 31 biologic programs targeting Respiratory Syncytial Virus Infection. It is currently in Preclinical.
2
Indications
4
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Fluzone
SanofiPreclinical
Fluzone
GSKPreclinical
Crestor
AstraZenecaPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
Antihistamine
Arrowhead PharmaceuticalsPreclinical
Focetria
CChiltern Pesquisa Clinica Ltda
Preclinical
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
PD-1/PD-L1 Inhibitors
CChuangzhen Chen
Preclinical
RSV A Memphis 37
IImperial College London
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Respiratory Syncytial Virus1 trial
Respiratory Syncytial Virus Infection1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RSV A Memphis 37. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- IImperial College London